A Phase 3 interventional study of sitagliptin and Comparator: glimepiride in Type 2 Diabetes Mellitus, Non Insulin Dependent and Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 46th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,035 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 14th largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 86 in phase 3, and was the 53rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride. This study will also see if this treatment is safe and tolerable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitagliptin
Drug: sitagliptin · Drug: open-label metformin
glimepiride
Drug: Comparator: glimepiride · Drug: open-label metformin
Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
Also known as: Januvia
glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
Also known as: metformin
Change From Baseline in HbA1c at Week 30
Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Week 0 to Week 30
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30
Change from baseline at Week 30 was defined as Week 30 minus Week 0.
Time frame: Week 0 to Week 30
Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30
Time frame: Week 0 to Week 30
Change From Baseline in Body Weight at Week 30
Change from baseline at Week 30 was defined as Week 30 minus Week 0.
Time frame: Week 0 to Week 30
Percent of Patients With A1C <7.0% at Week 30
Time frame: Week 30
Percent of Patients With A1C <6.5% at Week 30
Time frame: Week 30
Phase III First Patient In: 14-May-2008; Last Patient Last Visit: 27-Oct-2009; 109 study centers worldwide
| Milestone | Sitagliptin | Glimepiride |
|---|---|---|
| Started | 516 | 519 |
| Completed | 468 | 468 |
| Not completed | 48 | 51 |
| Withdrew: Adverse event | 11 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 5 | 4 |
| Withdrew: Lost to follow-up | 9 | 9 |
| Withdrew: Physician decision | 3 | 4 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal by subject | 11 | 16 |
| Withdrew: Other | 7 | 12 |
Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.
| Percent | Sitagliptin | Glimepiride |
|---|---|---|
| Change From Baseline in HbA1c at Week 30 | -0.47 (-0.55 to -0.39) | -0.54 (-0.62 to -0.45) |
Change from baseline at Week 30 was defined as Week 30 minus Week 0.
| mg/dL | Sitagliptin | Glimepiride |
|---|---|---|
| Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30 | -14.6 (-17.9 to -11.2) | -17.5 (-20.8 to -14.1) |
| Percentage of Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30 | 7.0 | 22.0 |
Change from baseline at Week 30 was defined as Week 30 minus Week 0.
| Kilograms | Sitagliptin | Glimepiride |
|---|---|---|
| Change From Baseline in Body Weight at Week 30 | -0.8 (-1.1 to -0.5) | 1.2 (0.9 to 1.5) |
| Percentage of Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Percent of Patients With A1C <7.0% at Week 30 | 52.4 | 59.6 |
| Percentage of Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Percent of Patients With A1C <6.5% at Week 30 | 21.2 | 27.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 16/516 (3.1%) | 58/519 (11.2%) |
| Glimepiride | — | 11/518 (2.1%) | 134/518 (25.9%) |
| Event | Sitagliptin | Glimepiride |
|---|---|---|
| Myocardial ischaemiaCardiac disorders | 2/516 | 0/518 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/516 | 0/518 |
| Inguinal herniaGastrointestinal disorders | 1/516 | 0/518 |
| MastitisInfections and infestations | 1/516 | 0/518 |
| Peritonsillar abscessInfections and infestations | 1/516 | 0/518 |
| Typhoid feverInfections and infestations | 1/516 | 0/518 |
| Humerus fractureInjury, poisoning and procedural complications | 1/516 | 0/518 |
| Patella fractureInjury, poisoning and procedural complications | 1/516 | 0/518 |
| Skin lacerationInjury, poisoning and procedural complications | 1/516 | 0/518 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/516 | 0/518 |
| Event | Sitagliptin | Glimepiride |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 36/519 | 114/518 |
| NasopharyngitisInfections and infestations | 25/519 | 36/518 |
| Age, Continuous(years) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 56.3 ± 9.7 | 56.2 ± 10.1 | 56.3 ± 9.9 |
| Sex: Female, Male(Participants) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Female | 232 | 240 | 472 |
| Male | 284 | 279 | 563 |
| Race/Ethnicity, Customized(participants) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| White | 297 | 298 | 595 |
| Black | 6 | 6 | 12 |
| Asian | 109 | 111 | 220 |
| American Indian/Alaska Native | 25 | 26 | 51 |
| Other | 79 | 78 | 157 |
| A1C (Hemoglobin A1c)(Percent) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 7.50 ± 0.70 | 7.51 ± 0.76 | 7.50 ± 0.73 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of May 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin